ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Emerging Nanozyme Strategies for Precision Breast Cancer Treatment.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Nanoimmunomodulation for cartilage repair in osteoarthritis: reprogramming the inflammatory joint microenvironment.International journal of pharmaceutics: X · 2026Review
- Nanozyme-based therapeutic strategies for traumatic brain injury.International journal of pharmaceutics: X · 2026Review
- Microbiota and head and neck cancers: Mechanistic insights and translational potential.Virulence · 2026Review
- An NIR-responsive FeS-loaded alginate hydrogel promotes diabetic wound healing through Nrf2 activation and macrophage polarization.International journal of pharmaceutics: X · 2026Article
- Biomaterial-based Drug delivery strategies for head and neck cancer: Local delivery, combination therapy, and translational challenges.International journal of pharmaceutics: X · 2026Review
- Colorectal cancer landscape from gut microbiota: Insights into mutations, epigenetic dysregulation, and immune microenvironment alterations.Virulence · 2026Review
- Review
- Engineered hollow Prussian blue nanoparticles for synergistic anti-inflammatory therapy in sepsis.Materials today. Bio · 2026Article
- Mediating role of telomere shortening in dioxin-like polychlorinated biphenyls associated cognitive decline in children.Environmental health : a global access science source · 2026Article
- Recent advances in engineered nanozymes for precision lung cancer therapy.Materials today. Bio · 2026Review
- Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy.MedComm · 2026Review
- Functionalized polysaccharides for infection-resistant and regenerative therapies in gynecology.International journal of pharmaceutics: X · 2026Review
- Bone-seeking nanomaterials for rebalancing bone remodeling in osteoporosis.International journal of pharmaceutics: X · 2026Review
- Pan-cancer multi-omics analysis identifies SYNGR4 as a novel clinical prognostic biomarker and therapeutic target in lung adenocarcinoma.Discover oncology · 2026Article
- Nano-armed bcg delivers Cu-Fe MOF to trigger dual cell death in bladder cancer.Journal of nanobiotechnology · 2026Article
- Engineered Nanozymes for Colorectal Cancer Therapy: Catalytic Reprogramming of the Tumor Microenvironment.International journal of nanomedicine · 2026Review
- Precise Catalysis and Immune Activation: New Strategies for Tumor Immunotherapy with Cascade Nanozymes.International journal of nanomedicine · 2026Review
- Emerging Nanozyme Strategies for Precision Breast Cancer Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Mesoporous silica nanoparticles--based functional platforms for breast cancer therapy: technological advancements.Frontiers in chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Breast cancer, the most common malignant tumor among women worldwide, poses a significant challenge to public health due to its high incidence and mortality rates. While traditional treatment strategies such as surgery, radiation therapy, chemotherapy and targeted therapy have made significant progress, limitations such as tumor heterogeneity, drug resistance, distant metastasis, and systemic side effects remain urgent issues to address. Nanozymes, a new type of nanomaterial with natural enzyme activity, have provided revolutionary opportunities for the precise treatment of breast cancer. This article aims to comprehensively review the progress of nanozyme applications in breast cancer treatment, focusing on how they can improve immunotherapy by regulating the tumor microenvironment and enhancing the immune response, optimize chemotherapy by improving drug delivery efficiency and overcoming drug resistance, and develop photothermal/photodynamic combination therapy to enhance therapeutic efficacy. In addition, this paper will also analyze in depth the key challenges faced by nanozymes in the clinical translation of breast cancer, such as biocompatibility, targeting efficiency, controllability, and large-scale production, and look forward to its broad prospects as a new treatment method combined with existing strategies, with the hope of providing new ideas for the precise, efficient, and low-toxicity treatment of breast cancer in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.